Regulatory milestones

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $0.60 to $24.21 last week after completing submission of a rolling NDA to FDA seeking accelerated approval of ponatinib to treat resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ariad, which requested Priority Review, began the submission in late July, and hopes to launch the product in the U.S. in 1Q13.